Third antigen’s a charm: Gilead pens deal with Merus for up to three trispecific antibodies 

Gilead has en­list­ed Merus in a re­search deal to de­vel­op new trispe­cif­ic an­ti­bod­ies that can har­ness the im­mune sys­tem to fight can­cer.

Merus will re­ceive $56 mil­lion up­front plus a $25 mil­lion in­vest­ment from Gilead. In ex­change, Merus will con­duct ear­ly-stage re­search on two trispe­cif­ic an­ti­body pro­grams, with an op­tion for a third. Gilead has the right to li­cense the pro­grams from Merus af­ter ear­ly re­search, af­ter which Gilead will be re­spon­si­ble for ad­di­tion­al R&D and com­mer­cial­iza­tion for the pro­grams.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.